|
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448
March 19, 2004
Ms. Eve Damiano
OraSure Technologies
150 Webster Street
Bethlehem, PA 18015-1389
Re: BP010047/12
Product: OraQuick Rapid HIV-1/2 Antibody Test
Device Code: MTL
Date Received: 16-DEC-03
Dear Ms. Damiano:
The Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) has completed its review of your premarket approval supplement (PMA Supplement) for the OraQuick Rapid HIV-1/2 Antibody Test. This supplement is to allow for an addition to the intended use statement, to include the detection of antibodies for HIV-2. We are pleased to inform you that the PMA Supplement is approved. You may continue commercial distribution of the device upon receipt of this letter.
If you have any questions concerning this approval order, please contact Hilary Cooper at (301) 827-5307.
Sincerely,
--- signature ---
Hira L. Nakhasi, Ph.D.
Director
Division of Emerging and Transfusion Transmitted Diseases
Office of Blood Research and Review
Center for Biologics Evaluation and Research
|
